{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:35:40Z","timestamp":1771331740623,"version":"3.50.1"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82074226 82030120"],"award-info":[{"award-number":["82074226 82030120"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> Patients with stable coronary artery disease (SCAD) still have a higher risk of adverse cardiovascular events. Shexiang Baoxin Pill (SBP) is widely used as a complementary and alternative treatment for SCAD. This study aimed to further verify the therapeutic effect and safety of SBP on SCAD.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Seven databases were involved in this meta-analysis as of 1 June 2022. Data was collected from all the randomized controlled trials (RCTs) of the combination of SBP and conventional western medicine (CWM) in treating SCAD which was conducted by two independent authors. Risk of bias was assessed using the Cochrane risk-of-bias 2.0 (RoB2.0) tool, and the meta-analysis was accomplished with Review Manager 5.3. Furthermore, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) profiler 3.2.2 software was selected to grade the current evidence in our findings.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> 42 articles, involving 6,694 patients were screened among all the 1,374 records in the analysis. The results demonstrated that the combination therapy was more efficient than CWM alone in lowering the incidence of major adverse cardiovascular events (MACE, RR = 0.50, 95% CI: 0.37 to 0.68, <jats:italic>p<\/jats:italic> &amp;lt; 0.00001) and ameliorating the total effective rate of angina symptom improvement (RR = 1.23, 95% CI: 1.19 to 1.28, <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), the effective rate of electrocardiogram improvement (RR = 1.34, 95% CI: 1.26 to 1.43, <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), the frequency of angina pectoris (MD = \u22122.83, 95% CI: \u22123.62 to \u22122.05, <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), and the duration of angina pectoris (MD = \u22121.32, 95% CI: \u22122.04 to \u22120.61, <jats:italic>p<\/jats:italic> = 0.0003). We also found that, after SBP treatment, a more positive blood lipid level and left ventricular ejection fraction without the increase in adverse cases were calculated in our meta-analysis. What\u2019s more, Subgroup analysis indicated that treatment duration may be the source of heterogeneity. The certainty of the evidence for MACE, and electrocardiogram improvement exhibited moderate certainty, and the certainty of the evidence for the remaining outcomes was judged as low certainty. The trial sequential analysis further affirmed the clinical efficacy of SBP.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The available evidence indicates that SBP may be an effective therapeutic option in patients with SCAD. However, considering the inferior quality and inconsistent results in the included trials, further rigorous RCTs are required.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero<\/jats:ext-link>, identifier [CRD42022334529].<\/jats:p>","DOI":"10.3389\/fphar.2022.1002713","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T04:30:50Z","timestamp":1668400250000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and safety of Shexiang Baoxin Pill for stable coronary artery disease: A systematic review and meta-analysis of 42 randomized controlled trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Jingjing","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengle","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinlu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1756-5391.2010.01055.x","article-title":"Improving reporting of adverse events and adverse drug reactions following injections of Chinese materia medica","volume":"3","author":"Bian","year":"2010","journal-title":"J. Evid. Based. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.7661\/j.cjim.20170801.307","article-title":"Chinese expert Consensus on shexiang baoxin pills for the treatment of coronary heart disease and angina pectoris","volume":"38","year":"2018","journal-title":"Chin. J. Integr. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"10506","DOI":"10.21037\/apm-21-2233","article-title":"A systematic review and meta-analysis of clinical research on treating angina pectoris of coronary heart disease with traditional Chinese medicine to promote blood circulation and remove blood stasis","volume":"10","author":"Chen","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.13457\/j.cnki.jncm.2019.10.025","article-title":"Observation of shexiang baoxin pills for stable Angina pectoris of coronary heart disease and its regulating effect on ROS and CT-1 in serum","volume":"51","author":"Chen","year":"2020","journal-title":"Chin. J. New Chin. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"W7-W20","DOI":"10.7326\/IsTranslatedFrom_M17-2977_1","article-title":"CONSORT extension for Chinese herbal medicine formulas 2017: Recommendations, explanation, and elaboration (traditional Chinese version)","volume":"167","author":"Cheng","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3969\/j.issn.1672-2779.2014.21.035","article-title":"Shexiang Baoxin Pill combined with Xiaoxintong in the treatment of 45 cases of stable angina pectoris","volume":"2014","author":"Cheng","year":"2014","journal-title":"Chin. Med. Mod. Distance Educ. China"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.13288\/j.11-2166\/r.2019.21.015","article-title":"Guidelines for TCM diagnosis and treatment of stable angina pectoris of coronary heart disease","volume":"60","year":"2019","journal-title":"J. Tradit. Chin. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/ehjqcco\/qcz002","article-title":"Clinical outcomes, pharmacological treatment, and quality of life of patients with stable coronary artery diseases managed by cardiologists: 1-year results of the START study","volume":"5","author":"De Luca","year":"2019","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"B10","first-page":"249","article-title":"Observation on the curative effect of Shexiang Baoxin Pill in the treatment of stable angina pectoris","volume":"26","author":"Ding","year":"2016","journal-title":"China Heal Care Nutr."},{"key":"B11","doi-asserted-by":"publisher","first-page":"43632","DOI":"10.1038\/srep43632","article-title":"A network-based method for mechanistic investigation of Shexiang Baoxin Pill's treatment of cardiovascular diseases","volume":"7","author":"Fang","year":"2017","journal-title":"Sci. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1001\/jama.2013.282183","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","article-title":"2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American college of Cardiology foundation\/American heart association task force on practice guidelines, and the American college of physicians, American association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons","volume":"60","author":"Fihn","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.12102\/ji.ssn.1672-1349.2021.21.040","article-title":"Observation on the curative effect of Shexiang Baoxin Pill in the adjuvant treatment of stable coronary heart disease","volume":"19","author":"Gao","year":"2021","journal-title":"Chin. J. Integr. Med. Cardio-\/Cerebrovascuiar Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/CM9.0000000000001257","article-title":"Efficacy and safety of shexiang baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: A multicenter, double-blind, placebo-controlled phase IV randomized clinical trial","volume":"134","author":"Ge","year":"2020","journal-title":"Chin. Med. J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/jebm.12018","article-title":"Understanding GRADE: An introduction","volume":"6","author":"Goldet","year":"2013","journal-title":"J. Evid. Based. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"7644648","DOI":"10.1155\/2021\/7644648","article-title":"Shexiang baoxin pill for acute myocardial infarction: Clinical evidence and molecular mechanism of antioxidative stress","volume":"2021","author":"Guo","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.3969\/j.issn.1008-8849.2012.22.018","article-title":"Observation of curative effect of shexiang baoxin pill in treating stable Angina pectoris of senile coronary heart disease","volume":"21","author":"Guo","year":"2012","journal-title":"Mod. J. Integr. Traditional Chin. West. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3969\/j.issn.1006-5180.2015.15.018","article-title":"Observation on the effect of Shexiang Baoxin Pill combined with Xiaoxintong in the treatment of senile stable angina pectoris","volume":"2015","author":"Hou","year":"2015","journal-title":"Chin. J. Rural Med. Pharm."},{"key":"B20","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/FJC.0000000000000967","article-title":"Shexiang baoxin pill attenuates ischemic injury by promoting angiogenesis by activation of aldehyde dehydrogenase 2","volume":"77","author":"Hu","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3969\/j.issn.1672-1349.2014.02.025","article-title":"Shexiang Baoxin Pill combined with aspirin in the treatment of 60 cases of senile blood stasis type stable angina pectoris","volume":"12","author":"Huang","year":"2014","journal-title":"Chin. J. Integr. Med. Cardio-\/Cerebrovascuiar Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e14638","DOI":"10.1097\/MD.0000000000014638","article-title":"Compound salvia pellet might be more effective and safer for chronic stable angina pectoris compared with nitrates: A systematic review and meta-analysis of randomized controlled trials","volume":"98","author":"Huiping","year":"2019","journal-title":"Med. Baltim."},{"key":"B23","first-page":"47","article-title":"Clinical observation of Shexiang Baoxin pills combined with Western medicine in the treatment of 68 cases of stable angina pectoris","volume":"23","author":"Ji","year":"2015","journal-title":"China's Naturop."},{"key":"B24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3969\/j.issn.1672-2779.2012.13.033","article-title":"Observation of curative effect of shexiang baoxin pill on ischemic cardiomyopathy","volume":"10","author":"Jiang","year":"2012","journal-title":"Chin. Med. Mod. Distance Educ. China"},{"key":"B25","doi-asserted-by":"publisher","first-page":"ITC81-ITC96","DOI":"10.7326\/AITC201712050","article-title":"Dyslipidemia","volume":"167","author":"Kopin","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ijcard.2020.10.016","article-title":"Revascularization versus medical therapy for the treatment of stable coronary artery disease: A meta-analysis of contemporary randomized controlled trials","volume":"324","author":"Laukkanen","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"702110","DOI":"10.3389\/fcvm.2021.702110","article-title":"Traditional Chinese medicine for coronary artery disease treatment: Clinical evidence from randomized controlled trials","volume":"8","author":"Liang","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.14164\/j.cnki.cn11-5581\/r.2019.08.076","article-title":"Observation of curative effect of shexiang baoxin pill on ischemic cardiomyopathy","volume":"13","author":"Liao","year":"2019","journal-title":"Chin. J. Mod. Drug Appl."},{"key":"B29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.16040\/j.cnki.cn15-1101.2014.23.036","article-title":"Clinical observation of Shexiang Baoxin Pill combined with Xiaoxintong in the treatment of stable angina pectoris","volume":"33","author":"Liu","year":"2014","journal-title":"Inn. Mong. J. Traditional Chin. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3969\/j.issn.1008-0074.2018.06.17","article-title":"Therapeutic effect and safety of oral musk Baoxin pill in patients with stable angina pectoris of coronary heart disease","volume":"27","author":"Liu","year":"2018","journal-title":"Chin. J. Cardiovasc Rehabil. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3969\/j.issn.1674-4055.2019.03.05","article-title":"Interpretation of the risk of bias assessment tool for randomized controlled trials, rev. 2.0. 2016:8565907","volume":"11","author":"Liu","year":"2019","journal-title":"Chin. J. Evid. Based Cardiovasc Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"8565907","DOI":"10.1155\/2016\/8565907","article-title":"The effect of Chinese herbal medicine gualouxiebaibanxia decoction for the treatment of angina pectoris: A systematic review","volume":"2016","author":"Liu","year":"2016","journal-title":"Evid. Based. Complement. Altern. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"6710759","DOI":"10.1155\/2019\/6710759","article-title":"Shexiang baoxin pill alleviates the atherosclerotic lesions in mice via improving inflammation response and inhibiting lipid accumulation in the arterial wall","volume":"2019","author":"Lu","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"B34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3969\/j.issn.1674-4721.2012.32.058","article-title":"Clinical observation of shexiang baoxin pill in treating 64 cases of coronary heart disease with stable Angina pectoris","volume":"19","author":"Lv","year":"2018","journal-title":"China Mod. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14033\/j.cnki.cfmr.2016.27.012","article-title":"Effects of shexiang baoxin pill on ultrasound, inflammatory index and blood lipid in old myocardial infarction","volume":"14","author":"Miao","year":"2016","journal-title":"Chin. Foreign Med. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: The task force on the management of stable coronary artery disease of the European society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur. Heart J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1161\/CIR.0000000000000366","article-title":"Executive summary: Heart disease and stroke statistics-2016 update: A report from the American heart association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/jijsu\/2021\/105906","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int. J. Surg."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.3969\/jissn.1008-0805.2019.12.077.012","article-title":"Meta analysis of shexiang baoxin pills in treatment of stable Angina pectoris","volume":"30","author":"Pan","year":"2019","journal-title":"Lishizhen Med. Materia Medica Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.13457\/j.cnki.jncm.2022.04.012","article-title":"Clinical study on shexiang baoxin pills combined with metoprolol for stable Angina pectoris of coronary heart disease in senile patients","volume":"54","author":"Pan","year":"2022","journal-title":"J. New Chin. Med."},{"key":"B41","first-page":"112","article-title":"Effect of shexiang baoxin pill on cardiac function of patients with ischemic heart disease","volume":"13","author":"Pan","year":"2016","journal-title":"J. North Pharm."},{"key":"B42","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3969\/j.issn.1672-1349.2017.04.020","article-title":"Observation on the curative effect of Shexiang Baoxin Pill in the treatment of stable angina pectoris","volume":"15","author":"Peng","year":"2017","journal-title":"Chin. J. Integr. Med. Cardio-\/Cerebrovascuiar Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3969\/j.issn.1671-7813.2011.12.19","article-title":"Heart pill of musk combined with western medicine treatment of stable Angina pectoris 65 cases of blood stasis","volume":"25","author":"Shi","year":"2011","journal-title":"J. Pract. Traditional Chin. Intern. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/ptr.6474","article-title":"Corn silk decoction for blood lipid in patients with angina pectoris: A systematic review and meta-analysis","volume":"33","author":"Shi","year":"2019","journal-title":"Phytother. Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3969\/j.issn.1002-7386.2010.09.091","article-title":"Clinical observation of shexiang baoxin pill in treating stable Angina pectoris","volume":"32","author":"Sun","year":"2010","journal-title":"Hebei Med. J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3969\/j.issn.1004-437X2013.04.056","article-title":"Clinical observation of shexiang baoxin pill in treating stable Angina pectoris","volume":"22","author":"Sun","year":"2013","journal-title":"Henan Med. Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.16367\/j.issn.1003-5028.2015.02.0108","article-title":"Effect of shexiang baoxin pill on clinical symptoms of elderly patients with stable Angina pectoris","volume":"35","author":"Tan","year":"2015","journal-title":"Henan Tradit. Chin. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"90","DOI":"10.16282\/j.cnki.cn11-9336\/r.2015.23.053","article-title":"Observation on the curative effect of Shexiang Baoxin Pill in the treatment of stable angina pectoris","volume":"3","author":"Wang","year":"2015","journal-title":"Cardiovasc. Dis. J. Integr. traditional Chin. West. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3969\/j.issn.1006-1959.2014.21.327","article-title":"Clinical observation of Shexiang Baoxin Pill in the treatment of senile stable exertional angina pectoris","volume":"2014","author":"Wang","year":"2014","journal-title":"Med. Inf."},{"key":"B50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3969\/jissn.1009_816x.2018.01.022","article-title":"Observation of curative effect of oral administration of Shexiang Baoxin pills in patients with stable angina pectoris","volume":"18","author":"Wang","year":"2018","journal-title":"Prev. Treat. Cardio-Cerebral-Vascular Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"751050","DOI":"10.3389\/fphar.2021.751050","article-title":"Effects of shexiang baoxin pill for coronary microvascular function: A systematic review and meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3969\/j.issn.1672-5433.2016.09.001","article-title":"Long-term curative effect of heart-protecting musk pill on stable Angina pectoris accompanied by hyperlipemia","volume":"13","author":"Wang","year":"2016","journal-title":"China Licens. Pharm."},{"key":"B53","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3969\/j.issn.1674-2257.2020.03.022","article-title":"Clinical efficacy of Shexiang Baoxin Pill combined with diltiazem in the treatment of elderly patients with stable angina pectoris of coronary heart disease","volume":"15","author":"Wang","year":"2020","journal-title":"J. Chengdu Med. Coll."},{"key":"B54","doi-asserted-by":"publisher","first-page":"128","DOI":"10.13935\/j.cnki.sjzx.180135","article-title":"Clinical therapeutic effects on old myocardial infarction treated with shexiang baoxin pills and trimetazidine hydrochloride tablets in the patients","volume":"13","author":"Wang","year":"2018","journal-title":"World J. Integr. Traditional West. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2672516","DOI":"10.1155\/2021\/2672516","article-title":"Efficacy and safety of shexiang baoxin pill for coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis","volume":"2021","author":"Wei","year":"2021","journal-title":"Evid. Based. Complement. Altern. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3969\/j.issn.1007-614x.2012.14.216","article-title":"Observation and analysis of curative effect of shexiang baoxin pill in treating 88 cases of ischemic cardiomyopathy","volume":"14","author":"Wu","year":"2012","journal-title":"Chin. Community Dr."},{"key":"B57","doi-asserted-by":"publisher","first-page":"165","DOI":"10.14163\/j.cnki.11-5547\/r.2016.01.124","article-title":"Influence of oral administration of Shexiang Baoxin Pill for at least 6 months on clinical events in patients with stable angina pectoris","volume":"2016","author":"Xia","year":"2016","journal-title":"China Prac. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3969\/j.issn.1001-1528.2021.07.017","article-title":"Clinical effects of Shexiang Baoxin Pills combined with conventional treatment on stable angina pectoris in patients with coronary artery diseases","volume":"43","author":"Xia","year":"2021","journal-title":"Chin. Tradit. Pat. Med."},{"key":"B59","first-page":"21","article-title":"Effects of Shexiang Baoxin Pill combined with nitroglycerin on angina attack and inflammatory factor levels in patients with stable angina pectoris of coronary heart disease","volume":"11","author":"Xie","year":"2021","journal-title":"Prev. Treat. Cardiovasc. Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3969\/j.issn.1009-0126.2010.08.008","article-title":"Clinical observation on the efficacy of Shexiang Baoxin pills in the treatment of SAP in the elderly patients","volume":"12","author":"Xu","year":"2010","journal-title":"Chin. J. Geriatr. Heart Brain Vessel Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3969\/j.issn.1672-1349.2013.03.018","article-title":"Effect of Shexiang Baoxin Pill on platelet aggregation in patients with stable angina pectoris","volume":"11","author":"Yang","year":"2013","journal-title":"Chin. J. Integr. Med. Cardio-\/Cerebrovascuiar Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12939-022-01666-9","article-title":"Strategies comparison in response to the two waves of COVID-19 in the United States and India","volume":"29","author":"Yang","year":"2022","journal-title":"Int. J. Equity Health"},{"key":"B63","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2019.11.005","article-title":"Mechanism of angiogenesis promotion with Shexiang Baoxin Pills by regulating function and signaling pathway of endothelial cells through macrophages","volume":"292","author":"Zhang","year":"2020","journal-title":"Atherosclerosis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3969\/j.issn.1002-7386.2022.04.008","article-title":"Efficacy evaluation of Shexiangbaoxin pills in treatment of stable angina pectoris with syndrome of yang deficiency and cold congelation and its effects on inflammatory factors CD31 and CD62P","volume":"44","author":"Zhao","year":"2022","journal-title":"Hebei Med. J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"74+76","DOI":"10.3969\/j.issn.1007-614x.2018.3.45","article-title":"Efficacy of Shexiang Baoxin Pill in the treatment of elderly patients with stable angina pectoris","volume":"34","author":"Zhao","year":"2018","journal-title":"Chin. Community Dr."},{"key":"B66","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3969\/j.issn.1005-0019.2018.14.127","article-title":"Clinical observation of shexiang baoxin pill in adjuvant treatment of chronic stable Angina pectoris","volume":"2018","author":"Zhao","year":"2018","journal-title":"Health Horiz."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3969\/j.issn.1002-7386.2014.07.025","article-title":"Clinical analysis of Shexiang Baoxin Pill in the treatment of stable angina pectoris complicated with carotid atherosclerosis","volume":"2014","author":"Zhao","year":"2014","journal-title":"Hebei Med. J."},{"key":"B68","first-page":"1934","article-title":"Clinical efficacy and safety observation of Shexiang Baoxin Pill combined with diltiazem in the treatment of stable angina pectoris in elderly patients with coronary heart disease","volume":"45","author":"Zhao","year":"2021","journal-title":"Guizhou Med. J."},{"key":"B69","first-page":"100","article-title":"Efficacy of Shexiang Baoxin Pill combined with diltiazem in the treatment of senile coronary heart disease with stable angina pectoris","volume":"2021","author":"Zhou","year":"2021","journal-title":"Health Horiz."},{"key":"B70","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3969\/j.issn.1672-1349.2013.02.008","article-title":"Effect of shexiang baoxin pill combined with aspirin on serum adiponectin, endothelin-1, nitric oxide in stable Angina pectoris","volume":"11","author":"Zou","year":"2013","journal-title":"Chin. J. Integr. Med. Cardio-\/Cerebrovascuiar Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1002713\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T04:31:23Z","timestamp":1668400283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1002713\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":70,"alternative-id":["10.3389\/fphar.2022.1002713"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1002713","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"article-number":"1002713"}}